Developmental exposure to fenproporex: reproductive and morphological evaluation.
This study was designed to evaluate the maternal toxicity and teratogenicity of fenproporex, one of the most widely-used anorectic drugs in many countries, including Brazil. Three periods of exposure were evaluated: (a) 30 days before mating; (b) from gestational day (GD) 0 to 14; and (c) 30 days before mating and during pregnancy, until GD 14. Female mice from experimental groups received, by gavage, 15 mg/kg of fenproporex. Treatment with fenproporex increased ambulation of dams in the open-field test and did not influence the mobility in the forced-swimming test. There was no significant difference in maternal weight gain between the controls and fenproporex-treated groups, although fenproporex treatment reduced the gravid uterus weight. No significant difference was observed in postimplantation loss, fetal viability and sex ratio. In addition, this compound did not impair intra-uterine growth. The reduction in the number of implantations in the groups receiving fenproporex indicates that this drug may have an adverse effect on implantation. Fenproporex treatment also increased the number of fetuses presenting small kidneys and cervical ribs. The present results indicate that fenproporex, in the dose and exposure periods tested, appears to exhibit a low maternal toxicity and teratogenic potential in mice.
Moreira
C Q
CQ
Department of Biology, Center of Biological Sciences, Londrina State University, Londrina, PR, Brazil.
Faria
M J S S
MJ
Baroneza
J E
JE
Oliveira
R J
RJ
Moreira
E G
EG
D000662:Amphetamines / Q000633:toxicity*; D000818:Animals; D001067:Appetite Depressants / Q000633:toxicity*; D005260:Female; D008297:Male; D018811:Maternal Exposure; D051379:Mice; D011247:Pregnancy; D013723:Teratogens / Q000633:toxicity*
D000662:Amphetamines; D001067:Appetite Depressants; D013723:Teratogens; C026013:fenproporex